Scientific evidence

A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients with Non-Dysplastic Barrett’s Esophagus: Case Reports from a Gastrointestinal Surgery Center

Sep 2023

TissueCypher demonstrated clinical utility in NDBE patients by guiding risk-aligned upstaging of care and potential improved health outcomes in BE patients.

Author: Tseng D, et al.

Publication: Poster presentation (61) at AFS 2023, Dallas

The importance of incorporating drug-drug interactions and lifestyle factors in pharmacogenomics-guided medication management for patients with major depressive disorder in a randomized controlled trial

Sep 2023

In this study, drug-drug interactions accounted for 32% of all IDgenetix-guided drug recommendations, and lifestyle factors accounted for 11%. Incorporating these non-genetic factors in IDgenetix testing significantly impacts the number of drug recommendations and improves remission rates in patients with moderate to severe depression.

Author: Cao F, et al.

Publication: Poster at Psych Congress 2023

The tissue systems pathology-9 test provides clinically-impactful risk stratification in patients with Barrett’s esophagus: clinical experience in a multicenter cohort

Aug 2023

This study evaluated the use of the validated, commercially-available tissue systems pathology test (TissueCypher, TSP-9) to risk-stratify BE patients in a large clinical practice cohort.

Author: Villa N, et al.

Publication: Diseases of the Esophagus

31-gene expression profile testing in cutaneous melanoma and survival outcomes in a population-based analysis: A SEER collaboration

Jun 2023

Study data from Castle Biosciences' collaboration with the National Cancer Institutes SEER program registries.

Author: Bailey C, et al.

Publication: JCO-PO

Multi-colored lesion with uncertain malignant potential

Jun 2023

Conflicting clinical and histopathological findings are resolved with the use of GEP test results.

Atypical melanocytic proliferation on sensitive preauricular check

Jun 2023

Histopathological assessment of a melanocytic lesion on the check could not definitively rule out melanoma leading to the use of GEP prior to determining surgical management.

Asymmetrical pigmented lesion with high clinical suspicion for melanoma

Jun 2023

A 27-year-old female patient was seen by a primary care physician who recommended follow-up with a dermatologist for assessment of a concerning melanocytic lesion.

Abnormally pigmented lesion with uncertain malignant potential

Jun 2023

With benign GEP results, dermatopathologist adjusts diagnosis to a benign neoplasm and patient avoids re-excision.

Irregular papule with atypical histopathological findings and borderline/uncertain diagnosis

Jun 2023

Definitive diagnosis cannot be reached in an irregular, raised papule on the dorsal foot.

Improved response and remission rates in patients receiving IDgenetix-guided medication management for major depressive disorder

May 2023

In the study, patients whose medication management was guided by IDgenetix achieved a 35% increase in medication response and a 64% increase in remission compared to patients whose medication was not guided by the test

Author: Cao F, et al.

Publication: Poster at 2023 American Psychiatric Association (APA) Annual Meeting

Incorporation of the 40-gene expression profile (40-GEP) test to improve treatment decisions in high-risk cutaneous squamous cell carcinoma (cSCC) patients: case series and algorithm

May 2023

Cutaneous squamous cell carcinoma (cSCC) has become a significant public health issue due to its rapidly rising incidence and an estimated 1.8 million newly diagnosed cases annually. As with other cancers, treatment decisions for patients with cSCC are based primarily on a patient’s risk for poor outcomes. 

Author: Singh G, et al.

Publication: Clinical, Cosmetic and Investigational Dermatology

A tissue systems pathology test objectively risk-stratifies patients with Barrett's esophagus: results from a multicenter U.S. clinical experience

May 2023

Author: Villa N, et al.

Publication: Poster presentation (Tu1272) at DDW 2023, Chicago